Last reviewed · How we verify
Elontril — Competitive Intelligence Brief
phase 3
Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor
Metabolic
Small molecule
Live · refreshed every 30 min
Target snapshot
Elontril (Elontril) — Boehringer Ingelheim.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Elontril TARGET | Elontril | Boehringer Ingelheim | phase 3 | Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor | ||
| Wellbutrin | bupropion | GSK (GlaxoSmithKline) | marketed | NDRI (Norepinephrine-dopamine reuptake inhibitor) | Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor | 1985-12-30 |
| Wellbutrin | Wellbutrin | Mclean Hospital | marketed | Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Elontril — Competitive Intelligence Brief. https://druglandscape.com/ci/elontril. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab